mTOR: a pharmacologic target for autophagy regulation
mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR
regulates cell growth and proliferation in response to a wide range of cues, and its signaling …
regulates cell growth and proliferation in response to a wide range of cues, and its signaling …
Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation
Intrahepatic cholangiocarcinoma is the second most common primary hepatic tumor. Various
risk factors have been reported for intrahepatic cholangiocarcinoma, and the radiologic …
risk factors have been reported for intrahepatic cholangiocarcinoma, and the radiologic …
Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy
Autophagy is a stress response protecting cells from unfavorable conditions, such as nutrient
starvation. The class III phosphatidylinositol-3 kinase, Vps34, forms multiple complexes …
starvation. The class III phosphatidylinositol-3 kinase, Vps34, forms multiple complexes …
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
…, T Mekhail, D Planchard, YC Kim… - … England Journal of …, 2017 - Mass Medical Soc
Background Most patients with locally advanced, unresectable, non–small-cell lung cancer (NSCLC)
have disease progression despite definitive chemoradiotherapy (chemotherapy …
have disease progression despite definitive chemoradiotherapy (chemotherapy …
[HTML][HTML] Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
…, T Mekhail, D Planchard, YC Kim… - … England Journal of …, 2018 - Mass Medical Soc
Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage III, …
prolonged progression-free survival, as compared with placebo, among patients with stage III, …
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer (NSCLC). …
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer (NSCLC). …
Differential regulation of mTORC1 by leucine and glutamine
The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) integrates environmental
and intracellular signals to regulate cell growth. Amino acids stimulate mTORC1 activation …
and intracellular signals to regulate cell growth. Amino acids stimulate mTORC1 activation …
Alternative Wnt signaling activates YAP/TAZ
The transcriptional co-activators YAP and TAZ are key regulators of organ size and tissue
homeostasis, and their dysregulation contributes to human cancer. Here, we discover YAP/…
homeostasis, and their dysregulation contributes to human cancer. Here, we discover YAP/…
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway
YAP (Yes-associated protein) is a transcription co-activator in the Hippo tumour suppressor
pathway and controls cell growth, tissue homeostasis and organ size. YAP is inhibited by the …
pathway and controls cell growth, tissue homeostasis and organ size. YAP is inhibited by the …